Dose enlargement phase of the research: subjects have to have relapsed/refractory RMS or a stable malignant tumor (Ewing sarcoma, hepatoblastoma, neuroblastoma and Wilms tumor) by which treatment with vincristine/irinotecan is considered spine chemotherapy at relapse and also a scientific rationale to mix vincristine/irinotecan with regorafenib exists. which offered confined information https://sisunatovir-hydrochloride55443.smblogsites.com/18511839/5-simple-statements-about-gsk1324726a-explained